GlassScriptPhysician profile
Caitlin Featherston
NPI 1811738461
$1,906.87
in general payments reported to CMS, 2019-2025
21 companies · $1,424 in 2025
The $1,424 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $483 · 2025: $1,424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,889 · Education: $17.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,888.97 |
| Education | $17.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $256.92 | 2024-2025 | |
| Abbvie INC. | $250.35 | 2024-2025 | |
| Ucb, INC. | $240.12 | 2024-2025 | Briviact, Nayzilam |
| Argenx US, INC. | $215.94 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Emd Serono, INC. | $141.15 | 2025 | |
| Alexion Pharmaceuticals, INC. | $138.31 | 2024-2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $117.51 | 2025 | |
| Medtronic, INC. | $102.44 | 2025 | Intellis Adaptivestim |
| Teva Pharmaceuticals USA, INC. | $52.91 | 2024-2025 | Austedo Xr, Austedo Xr |
| Amneal Pharmaceuticals LLC | $51.66 | 2025 | Crexont |
| Pfizer INC. | $48.65 | 2024 | |
| Janssen Biotech, INC. | $46.60 | 2025 | |
| Lundbeck LLC | $45.63 | 2025 | Rexulti |
| Neurelis, INC. | $42.09 | 2025 | Valtoco |
| Sk Life Science, INC. | $28.06 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $26.32 | 2025 | Qutenza |
| Livanova USA, INC. | $24.21 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Tg Therapeutics, INC. | $23.28 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $21.22 | 2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $17.90 | 2025 | |
| Biomarin Pharmaceutical INC. | $15.60 | 2024 | Brineura |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlin Featherston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.